FDA clears Verve to begin U.S. study of gene-editing treatment for high cholesterol; Roche buys Telavant from Roivant for $7 billion

Taking stock of the drug industry, from the lab to the medicine chest

October 23, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FDA clears Verve to begin U.S. study of gene-editing treatment for high cholesterol The FDA's action removes a clinical hold on Verve's CRISPR-based therapy for high cholesterol, called VERVE-101, placed last November. By Adam Feuerstein STAT+ | Roche buys Telavant from Roivant for $7 billion, gaining bowel disease drug candidate Roche plans to start a Phase 3 trial of the drug, which has been studied as an ulcerative colitis treatment. By Andrew Joseph STAT+ | Results on Novartis prostate cancer therapy could expand its use The Phase 3 data amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. By Andrew Joseph Andrew Joseph/STAT STAT+ | In lung cancer, J&J data amount to latest salvo against AstraZeneca A competition has been brewing between Johnson & Johnson and AstraZeneca to gain an edge in the market for targeted lung cancer treatments. By Andrew Joseph STAT+ | Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions On Monday, data presented from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser